AI assistant
Salarius Pharmaceuticals, Inc. — Director's Dealing 2015
Jan 29, 2015
35494_dirs_2015-01-28_1f7d0261-ca6d-42f1-a889-4265050020e8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2015-01-28
Reporting Person: Hadfield Robert (General Counsel & Secretary)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.77 | 2024-05-18 | Common Stock (58377) | Direct | |
| Stock Option (right to buy) | $5.44 | 2024-11-13 | Common Stock (23350) | Direct |
Footnotes
F1: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on April 28, 2015, the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.
F2: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on November 14, 2015, the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.